On Wednesday, June 22, the FDA announced that it was investigating the death of an infant that occurred in January 2022 and is potentially related to Abbott baby formula. In a statement, the FDA said that it was notified of the death through a consumer complaint received on June 10, 2022. “The agency has initiated an investigation, given that the complaint referenced that the infant had consumed an Abbott product. However, the investigation of this most recent consumer complaint is in its preliminary stages and the agency will provide an update as it learns more,” the statement read.
The FDA has previously reported its review of complaints related to nine infant deaths. Two were found to be associated with the Abbott Nutrition Sturgis plant investigation. However, the FDA notes that, despite extensive investigation, the evidence does not rule in or rule out a definitive link between these infant deaths and the product produced at Abbott Nutrition’s Sturgis, Michigan-based plant.
Related Articles
-
The Office of the Inspector General is specifically examining whether FDA followed applicable policies and procedures related to conducting inspections of the manufacturing facility and overseeing Abbott’s initiation of the infant formula recall.
-
Abbott voluntarily recalled several products manufactured at its Sturgis, Michigan plant following complaints of Cronobacter sakazakii or Salmonella Newport illnesses in infants. One illness may have contributed to an infant death.
-
Hamburg, one of the longest-serving FDA commissioners in the modern era, told Reuters in an interview that her decision was prompted by the heavy demands of the job and the sheer length of time she has held the position.
-
The vote to appoint the new agency commissioner was overwhelming.
